Are Rekvina Labs Ltd latest results good or bad?

Rekvina Labs Ltd's latest financial results for Q4 FY26 indicate a complex situation characterized by both operational challenges and some signs of sequential improvement. The company reported net sales of ₹0.72 crores, which reflects a significant sequential growth of 105.71% from ₹0.35 crores in the previous quarter. This marks a notable recovery in revenue generation, as the company had previously reported zero sales in earlier quarters. Despite the increase in revenue, Rekvina Labs continues to face persistent profitability issues, reporting a net loss of ₹0.06 crores, although this represents a 50% improvement from the loss of ₹0.12 crores in Q3 FY26. The operating margin also showed some improvement, moving from -34.29% in Q3 FY26 to -8.33% in the latest quarter. This suggests that while the company is managing to grow its revenue, it still struggles to achieve positive operating cash flow. The market capitalization of Rekvina Labs stands at ₹20.00 crores, categorizing it as a micro-cap company. The broader context reveals that the pharmaceutical sector is experiencing robust growth, yet Rekvina Labs has not been able to capitalize on this momentum, indicating challenges in establishing a sustainable operational model. The company operates with a negative book value, which raises concerns about its long-term viability. Furthermore, there is a complete absence of institutional interest, with no holdings from foreign institutional investors, mutual funds, or insurance companies, reflecting a lack of confidence from professional investors. In summary, while Rekvina Labs has shown some sequential improvement in revenue and operating margins, the fundamental challenges regarding profitability, negative book value, and lack of institutional support remain significant. The company has seen an adjustment in its evaluation, indicating ongoing scrutiny regarding its operational viability and investment potential.